期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Targeted bile acids and gut microbiome profiles reveal the hepatoprotective effect of WZ tablet(Schisandra sphenanthera extract) against LCA-induced cholestasis 被引量:14
1
作者 LI Dong-Shun HUANG Quan-Fei +7 位作者 guan li-huan ZHANG Hui-Zhen LI Xi FU Kai-Li CHEN Yi-Xin WAN Jian-Bo HUANG Min BI Hui-Chang 《Chinese Journal of Natural Medicines》 SCIE CAS CSCD 2020年第3期211-218,共8页
Cholestasis is caused by the obstacle of bile formation or secretion and can develop into severe liver diseases. We previously reported the ethanol extract of Schisandra sphenanthera(Wuzhi tablet, WZ) can significantl... Cholestasis is caused by the obstacle of bile formation or secretion and can develop into severe liver diseases. We previously reported the ethanol extract of Schisandra sphenanthera(Wuzhi tablet, WZ) can significantly protect against lithocholic acid(LCA)-induced intrahepatic cholestasis in mice, partially due to the activation of PXR pathway and promotion of liver regeneration.However, the effect of WZ on the bile acids profile and gut microbiome in cholestastic mice remain unknown. In this study, the effect of WZ against LCA-induced liver injury was evaluated and its effect on the bile acids metabolome and gut microbiome profiles in cholestastic mice was further investigated. Targeted metabolomics analysis was performed to examine the change of bile acids in the serum, liver, intestine and feces. The change of intestinal flora were detected by the genomics method. Targeted metabolomics analysis revealed that WZ enhanced the excretion of bile acids from serum and liver to intestine and feces. Genomics analysis of gut microbiome showed that WZ can reverse LCA-induced gut microbiome disorder to the normal level. In conclusion, WZ protects against LCAinduced cholestastic liver injury by reversing abnormal bile acids profiles and alteration of gut microbiome. 展开更多
关键词 CHOLESTASIS Wuzhi TABLET SCHISANDRA sphenanthera METABOLOME GUT MICROBIOME Bile acids
原文传递
环磷酰胺所致小鼠肝损伤的动态变化 被引量:4
2
作者 黄灿 何法静 +7 位作者 杨潇 官丽欢 张思敏 周艳莹 范仕成 姚欣鹏 黄民 毕惠嫦 《药学学报》 CAS CSCD 北大核心 2019年第6期1062-1068,共7页
环磷酰胺(cyclophosphamide,CPA)是烷化剂类抗肿瘤药物,在体内由细胞色素P450酶代谢为4-羟基环磷酰胺发挥抗肿瘤作用。CPA除引起骨髓抑制、膀胱炎等毒性反应外,还会引起肝损伤。本研究旨在评估CPA在小鼠体内产生肝损伤的动态变化过程。... 环磷酰胺(cyclophosphamide,CPA)是烷化剂类抗肿瘤药物,在体内由细胞色素P450酶代谢为4-羟基环磷酰胺发挥抗肿瘤作用。CPA除引起骨髓抑制、膀胱炎等毒性反应外,还会引起肝损伤。本研究旨在评估CPA在小鼠体内产生肝损伤的动态变化过程。雄性BALB/c小鼠单次腹腔注射CPA(200 mg·kg^-1),分别于0、2、6、12和24 h后采集血清和肝脏样本进行生化和病理检测。动物实验方案经中山大学动物伦理委员会批准。结果表明,小鼠给予CPA 2 h后开始出现肝损伤,在12 h肝损伤最严重,血清天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)和丙二醛(MDA)显著升高,还原型谷胱甘肽(GSH)显著下降,广泛可见肝细胞水肿并伴有空泡变性,而24 h之后肝损伤显著改善。由于CPA产生氧化应激损伤,机体应激性激活核因子红细胞系相关因子-2(nuclear factorerythroid 2-related factor 2,NRF2)信号通路,上调NRF2下游醌氧化还原酶1(quinine oxidoreductase 1,NQO1)、血红素加氧酶-1(heme oxygenase-1,HO-1)、谷氨酰半胱氨酸合成酶催化亚基(glutamate-cysteine ligase catalytic subunit,GCLC)和谷氨酸半胱氨酸连接酶修饰亚基(glutamate cysteine modifier subunit,GCLM)的表达,从而抵抗氧化应激损伤。本研究阐明了CPA所致肝损伤随时间的动态变化过程,并探讨了NRF2介导的机体保护机制的动态变化,为抵抗CPA所致肝损伤提供了科学数据。 展开更多
关键词 环磷酰胺 肝损伤 氧化应激 核因子红细胞系相关因子-2
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部